top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
6 days ago
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
Jun 1
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 18
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 18, 2026 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026. Event: H.C. Wainwright 4th Annual BioConnect Investor Conference Format: Fireside Chat and 1x1 Meetings Date: Tuesday, May 19, 2026 Time: 10:30 – 11:00AM ET Location: New York, NY Event: Rothschi
May 18
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed
Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed
May 11
bottom of page